In our screening program for antitumor compounds, Streptomyces libani subsp. rubropurpureus
No. 6362 was found to produce a novel antitumor antibiotic, which was extracted from the fermentation broth and purified by a series of chromatographies to afford a crystalline solid named chromoxymycin.
The present paper describes the production, isolation, physico-chemical properties and biological activities of chromoxymycin. The taxonomy of the producing strain Streptomyces libani subsp. rubropurpureus No. 6362 and the structural studies on chromoxymycin are reported in separate papers1,2). Fermentation A loopful of mature slant culture of Streptomyces libani subsp. rubropurpureus No. 6362 was inoculated into a seed medium (160 ml) containing corn starch 1 %, glycerol I %, glucose 0.5 %, cotton seed flour 1 %, dried yeast 0.5 %, corn steep liquor 0.5 % and CaCO3 0.2%, (pH 6.5) in a 500-m1 Erlenmeyer flask and cultured at 30°C on a rotary shaker with 7.6 cm-throw at 220 rpm for 72 hours.
Fermentation studies were carried out in tank fermentors. A seed culture was shaken in the above mentioned Erlenmeyer flasks and then transferred at the rate of 2 % to 80 liters of the same seed medium in a 200-liter jar fermentor, which was stirred at 265 rpm at 30°C for 48 hours. A 35-liter portion of the seed jar fermentor was inoculated into 1,700 liters of production medium containing sucrose 2 %, peanut powder 1.5 %, molatein 0.5 %, NaI 0.00005 % and COCK • 12H2O 0.0004 in a 2,000-liter stainless steel fermentor which was operated at 30°C for 96 hours under aeration of 1,700 liters/minute and agitation of 180 rpm.
The antitumor antibiotic level in the fermentation broth was assayed by both high pressure liquid chromatography and cytotoxic activity against P388 murine leukemia cells in tissue culture.
Isolation and Purification
The fermentation broth (1,700 liters) was filtered with the aid of diatomaceous earth (5 kg twice and the extracts were combined. The extracts were concentrated in vacuo to a volume of 500 ml.
The oily materials obtained were mixed with silica gel (2 liters) and applied to a chromatography column using silica gel (5 liters). The column was washed with 12 liters of methanol and then eluted with 18 liters of methanol. The eluates were concentrated in vacuo to dryness. The crude sample was dissolved in 100 ml of 60% aqueous methanol containing 10 mm ammonium acetate, subjected to chromatography on a NS gel column (750 ml) and developed with 5 liters of 60% aqueous methanol containing 10 mm ammonium acetate. The active fractions eluted were concentrated in vacuo to a volume of I liter and passed through a column of HP-20 (300 ml). After washing with water, the column was eluted with 50% aqueous acetone (1 liter). The active fraction was evaporated to dryness under reduced pressure to yield purified active materials as free base (5.7 g). Yellow crystals were obtained from hot methanol (4 g).
Physico-chemical Properties
Chromoxymycin was readily soluble in water, slightly soluble in methanol and acetone, and insoluble in chloroform, hexane and diethyl ether. Chromoxymycin gave positive reactions to cerium sulfate, iodine and potassium permanganate reagents, though negative to Ehrlich, Dragendorff, Molisch and ninhydrin reactions. those of hedamycin3). However, the structure of chromoxymycin seems to be significantly different from that of hedamycin in view of UV spectral data and solubilities. Further structural studies on chromoxymycin are currently underway and will be published soon2).
Biological Activity
Antitumor Activity
The antitumor activity of chromoxymycin was determined in mice. Lymphocytic leukemia P388
and melanotic melanoma B16 were implanted intraperitoneally into BDF, mice ( Doxorubicin hydrochloride (Adriacin-Kyowa) was comparatively tested simultaneously as a reference compound.
Antitumor activity was evaluated by the mean survival time of a group of mice and also expressed by the T/C % value (mean survival time of treated group/mean survival time of control group, x 100).
The results are shown in Tables 2 and 3 . Chromoxymycin was quite active against leukemia P388 and melanoma B16. Doses between 12.5-400 mg/kg against P388 and 6.0-j 200 mg/kg against B16 resulted in significant increase in the life span of mice, respectively. Doxorubicin was also active against P388 at doses between 0.04-2.5 mg/kg and against B16 at doses between 0.03-2.0 mg/kg on the same schedule, respectively.
Antimicrobial Activity
The antimicrobial activity of chromoxymycin was determined by a serial broth dilution method in bouillon medium for bacteria and in Sabouraud medium for fungi and yeasts. The minimum inhibitory concentration (MIC) was expressed in terms of µg/ml after overnight incubation at 37°C for bacteria and 48-72 hours incubation at 28°C for fungi and yeasts. Chromoxymycin had weak antimicrobial activity against Staphylococcus aureus 209P (MIC 100 µg/ml) and Bacillus subtilis ATCC 6633 (MIC 25 pg/ml).
Acute Toxicity
The acute toxicity of chromoxymycin was determined in ddY mice (5 weeks old, female) by a single intravenous injection of graded doses of test compound into 5 mice. The LD50 was 1,000 mg/kg.
Discussion
From the 1H and 13C NMR spectral data, chromoxymycin was classified as being of the hedamycin type3). The UV spectra showed, however, that the main chromophore of chromoxymycin is different from that of the hedamycin group of antibiotics such as hedamycin3', pluramycin4), and kidamycin5,6). The structural elucidation of chromoxymycin is now in progress and will be published soon2). Another characteristic of chromoxymycin in its physico-chemical properties is that the antibiotic is readily soluble in water. This property is also distinct from those of the hedamycin group of compounds and may be of greater advantage for developing the antibiotic as a clinical agent.
Chromoxymycin was approximately 80 times less toxic than pluramycin A in the LD50 determination in mice by single administration6, 7) In addition, chromoxymycin was quite active in murine tumor systems including P388 and B16 over a wide range of extremely high doses. In vivo activity was reproducibly demonstrated at doses much more than 100 mg/kg. Further in vivo evaluation of the antitumor activities of this compound is now progress in the Division of Cancer Treatment, National Cancer Institute (USA).
